PMID- 30150886
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 1428-2526 (Print)
IS  - 1897-4309 (Electronic)
IS  - 1428-2526 (Linking)
VI  - 22
IP  - 2
DP  - 2018
TI  - Prognostic factors of primary fallopian tube carcinoma.
PG  - 99-104
LID - 10.5114/wo.2017.69590 [doi]
AB  - AIM OF THE STUDY: Fallopian tube cancer is very rare in the literature and so 
      there are not enough data about the therapeutic approaches. The approaches are 
      generally determined in accordance with the data obtained from ovarian cancer. 
      Many prognostic factors have been investigated in an effort to better estimate 
      patient outcome. Stage, age, and residual tumor after surgery are consistently 
      important prognostic factors. In this study, we aimed to evaluate the prognostic 
      factors and survival rates of primary fallopian tube cancer (PFTC), which is rare 
      among gynecological cancers. MATERIAL AND METHODS: Thirty-eight patients with a 
      diagnosis of PFTC were identified through the gynecologic oncology service 
      database of our Research and Training Hospital in the period 1995-2013. 
      Clinicopathological and surgical data were collected. All patients were evaluated 
      for survival and disease-free survival between the dates specified. RESULTS: A 
      significant relationship and correlation was found between optimal surgery and 
      life expectancy. Better results were obtained in patients treated with optimal 
      surgery. The survival probability was found to be higher in patients with lower 
      CA-125 levels and serous histologic type adenocarcinoma. CONCLUSIONS: Stage is 
      one of the factors affecting the survival probability. We determined that the 
      pathological type of tumor, the diameter of residual tumor remaining after 
      surgery, tumor grade, preoperative CA-125 levels and presence of ascites affect 
      the survival probability.
FAU - Akkaya, Emrah
AU  - Akkaya E
AD  - Obstetrics and Gynaecology Unit, Tepecik Obstetrics and Gynaecology Training and 
      Research Hospital, Izmir, Turkey.
FAU - Sanci, Muzaffer
AU  - Sanci M
AD  - Obstetrics and Gynaecology Unit, Tepecik Obstetrics and Gynaecology Training and 
      Research Hospital, Izmir, Turkey.
FAU - Kulhan, Nur G
AU  - Kulhan NG
AD  - Department of Obstetrics and Gynecology, Erzincan University, School of Medicine, 
      Turkey.
FAU - Kulhan, Mehmet
AU  - Kulhan M
AD  - Department of Obstetrics and Gynecology, Erzincan University, School of Medicine, 
      Turkey.
FAU - Nayki, Umit
AU  - Nayki U
AD  - Department of Obstetrics and Gynecology, Erzincan University, School of Medicine, 
      Turkey.
FAU - Nayki, Cenk
AU  - Nayki C
AD  - Department of Obstetrics and Gynecology, Erzincan University, School of Medicine, 
      Turkey.
FAU - Ata, Nahit
AU  - Ata N
AD  - Department of Obstetrics and Gynecology, Erzincan University, School of Medicine, 
      Turkey.
FAU - Ulug, Pasa
AU  - Ulug P
AD  - Department of Obstetrics and Gynecology, Erzincan University, School of Medicine, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20180409
PL  - Poland
TA  - Contemp Oncol (Pozn)
JT  - Contemporary oncology (Poznan, Poland)
JID - 101233223
PMC - PMC6103229
OTO - NOTNLM
OT  - management and treatment
OT  - primary fallopian tube cancer
OT  - prognostic factor
COIS- The authors declare no conflict of interest.
EDAT- 2018/08/29 06:00
MHDA- 2018/08/29 06:01
PMCR- 2018/01/01
CRDT- 2018/08/29 06:00
PHST- 2017/02/06 00:00 [received]
PHST- 2017/05/07 00:00 [accepted]
PHST- 2018/08/29 06:00 [entrez]
PHST- 2018/08/29 06:00 [pubmed]
PHST- 2018/08/29 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 69590 [pii]
AID - 10.5114/wo.2017.69590 [doi]
PST - ppublish
SO  - Contemp Oncol (Pozn). 2018;22(2):99-104. doi: 10.5114/wo.2017.69590. Epub 2018 
      Apr 9.